Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Recommendation of “Buy” from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received an average rating of “Buy” from the twelve research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $91.8889.

Separately, Raymond James Financial assumed coverage on shares of Janux Therapeutics in a research report on Friday, July 11th. They issued an “outperform” rating and a $65.00 target price for the company.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its stake in Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after buying an additional 2,502 shares during the period. Lazard Asset Management LLC boosted its stake in Janux Therapeutics by 64.8% during the second quarter. Lazard Asset Management LLC now owns 99,858 shares of the company’s stock worth $2,306,000 after buying an additional 39,278 shares during the period. Engineers Gate Manager LP boosted its stake in Janux Therapeutics by 115.0% during the second quarter. Engineers Gate Manager LP now owns 39,749 shares of the company’s stock worth $918,000 after buying an additional 21,258 shares during the period. BNP Paribas Financial Markets boosted its stake in Janux Therapeutics by 185.1% during the second quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock worth $177,000 after buying an additional 4,982 shares during the period. Finally, Bank of America Corp DE boosted its stake in Janux Therapeutics by 14.7% during the second quarter. Bank of America Corp DE now owns 859,423 shares of the company’s stock worth $19,853,000 after buying an additional 110,097 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Up 0.6%

Shares of NASDAQ JANX opened at $25.11 on Friday. The firm has a 50-day simple moving average of $24.61 and a 200-day simple moving average of $28.32. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -13.95 and a beta of 2.86. Janux Therapeutics has a 52 week low of $21.97 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07). As a group, equities research analysts expect that Janux Therapeutics will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.